Form 4: Credo Director Clyde Hosein Granted 1,540 RSUs

Sentiment:

Insider Transaction Report


Credo Technology Group Holding Ltd director Clyde Hosein was granted 1,540 restricted stock units, vesting based on service and future annual meetings.

Summary

  • Clyde Hosein, a director of Credo Technology Group Holding Ltd (CRDO), acquired 1,540 ordinary shares in the form of restricted stock units (RSUs).
  • The transaction occurred on October 15, 2025, with a reported price of $0, indicating a grant.
  • Following this transaction, Hosein beneficially owns 20,301 ordinary shares directly.
  • The 1,540 RSUs will vest upon the earlier of the one-year anniversary of the vesting commencement date (the day after the Issuer's 2025 Annual General Meeting) or the date of the Issuer's 2026 Annual General Meeting, contingent on continued service.

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a director, which is a positive for aligning interests and retention, but does not contain significant new financial or operational news.

Positives

  • Director Clyde Hosein received an equity grant of 1,540 restricted stock units, aligning his interests with shareholders.
  • The grant demonstrates continued commitment and incentivization for a key director.

Risks

  • Vesting of the restricted stock units is subject to Clyde Hosein's continued service through the vesting date.

Future Outlook

The filing indicates future vesting events for the granted restricted stock units, tied to the company's 2025 and 2026 Annual General Meetings and continued service.

Industry Context

Equity grants like restricted stock units are a common form of executive and director compensation in the technology sector, used to align management interests with long-term shareholder value and retain key talent.

Comparison to Industry Standards

  • The grant of restricted stock units (RSUs) to a director is a standard practice in publicly traded companies, particularly in the technology sector, for incentivizing long-term performance and retention.
  • The vesting schedule, tied to annual general meetings and continued service, is typical for such equity awards, comparable to practices at companies like Broadcom Inc. or Marvell Technology, Inc., which also utilize performance-based or time-based RSU grants for their leadership.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Power of AttorneyClyde Hosein granted James Laufman power of attorney to execute and file Forms 3, 4, and 5 on his behalf, ensuring compliance with Section 16 of the Exchange Act.2024-08-19Streamlines compliance for insider trading reporting for the director.

Stakeholder Impact

  • Shareholders: The equity grant aligns the director's interests with long-term shareholder value.

Next Steps

  • Vesting of the 1,540 restricted stock units will occur upon the earlier of the one-year anniversary of the vesting commencement date (day after the 2025 Annual General Meeting) or the 2026 Annual General Meeting.

Key Dates

DateDescription
2024-08-19Execution date of Power of Attorney by Clyde Hosein.
2025-10-15Date of acquisition of 1,540 restricted stock units by Clyde Hosein.
2025-10-17Signature date of the Form 4 filing.
Day after Issuer's 2025 Annual General MeetingVesting commencement date for restricted stock units.
Issuer's 2026 Annual General MeetingPotential vesting date for restricted stock units.

Recommendation

hold

This Form 4 filing details a routine equity grant to a director, which is a standard compensation practice and indicates continued alignment of management interests with shareholders. It does not provide new information that would fundamentally alter the investment thesis for Credo Technology Group Holding Ltd, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Credo Technology Group, CRDO, Clyde Hosein, Form 4, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Grant

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.